CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sangamo Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sangamo Therapeutics Inc
501 Canal Blvd.
Phone: (510) 970-6000p:510 970-6000 RICHMOND, CA  94084  United States Ticker: SGMOSGMO
Business Summary
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board H. StewartParker 68 6/1/2017 6/17/2014
President, Chief Executive Officer, Director Alexander D.Macrae 61 6/14/2016 6/1/2016
Chief Financial Officer, Senior Vice President PrathyushaDuraibabu 45 6/1/2021 6/14/2019
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
TxCell SA Allee de la Nertiere Les Cardoulines Valbonne France
Ceregene, Inc. 9381 Judicial Dr., Ste. 130 San Diego CA United States

Business Names
Business Name
CG Acquisition Sub, Inc.
Gendaq Limited
Sangamo Biosciences, Inc.
Sangamo Therapeutics France S.A.S.
SGMO
Txcell SA

General Information
Number of Employees: 405 (As of 12/31/2023)
Outstanding Shares: 208,646,870 (As of 11/7/2024)
Shareholders: 53
Stock Exchange: NASD
Federal Tax Id: 680359556
Fax Number: (302) 655-5049
Email Address: info@sangamo.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024